Agenda Topics- Antibodies, Methods for Development and Utility
- Biosimilars, Biobetters and Emerging Market Opportunities for Biotherapeutics
- Engineering T Cells for Cancer Therapy
- Monoclonal Antibodies and Methods for Development
- Technologies for Biotherapeutics Production
Sponsorship and Exhibition OpportunitiesExhibition Team, exhibitors@selectbio.com +44 (0) 1206 501654
|
Distinguished FacultyTudor Arvinte, Chairman and CEO, Therapeomics Inc/University of Geneva Steffen Goletz, Chief Executive & Scientific Officer, Glycotope GmbH Christopher Bravery, Director, Consulting on Advanced Biologicals Ltd Tim Sheehy, Director, Promega Corporation John Watson, Director, Promega Corporation Michael Tovey, Director, Institut Andre Lwoff/INSERM Robert Dillman, Executive Medical Director, Hoag Institute for Research and Education Enal Razvi, Managing Director, Select Biosciences Inc Vanessa Baeriswyl, Postdoc Researcher, EPFL Robert Hawkins, Professor, University of Manchester Paul Declerck, Professor, Katholieke Universiteit Leuven Paul Declerck, Professor, Katholieke Universiteit Leuven Kerry Chester, Professor, University College London Mark Cragg, Professor, University of Southampton Roy Jefferis, Professor Emeritus, University Of Birmingham Wilfried Bakker, Senior Research Scientist, Netherlands Vaccine Institute
|